Analyzing liver grafts to predict transplant outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to identify specific endothelial signatures in liver grafts after undergoing a process called HOPE, which is used prior to transplantation. It involves two patient cohorts: liver donors, who will have a biopsy taken for organ quality assessment, and liver recipients, who will undergo a study-specific biopsy after the transplant. The biopsies will be analyzed using histochemical and immunohistochemical techniques, as well as RT-PCR, to uncover molecular changes that could inform personalized perfusion treatments in the future.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* For Donors:

Availability of enough tissue for histological, immunohistochemical and RT-PCR analysis.

* HOPE performed on the liver graft prior to transplantation.
* For Recipients:
* Availability of enough tissue for histological, immunohistochemical and RT-PCR analysis.
* Age greater than/equal to 18 years.

Exclusion Criteria:

* None

Where it's running

• IRCCS Azienda Ospedaliero-Universitaria di Bologna
  Bologna, Italy Recruiting

Study contacts

• Principal investigator: Francesco Vasuri, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
• Study coordinator: Francecso Vasuri, MD
• Email: francesco.vasuri2@unibo.it
• Phone: 0512143761

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using gene analysis to improve diagnosis of liver transplant rejection

  This study is testing whether analyzing specific genes in liver transplant patients can help doctors diagnose rejection faster and more accurately.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna · NCT06734013

• Finding the right steroid dose for acute T cell rejection after kidney or kidney–pancreas transplant

  This trial will test whether lower doses of steroids work as well as higher doses to treat acute T cell–mediated rejection in people who have had a kidney or simultaneous kidney–pancreas transplant.

  Recruiting at 2 sites Phase 3 University of Sydney · Lambton, New South Wales and 29 other locations · NCT06474273

• Investigating white blood cells to develop new therapies for autoimmune diseases

  This study is trying to learn more about white blood cells from volunteers to help create new treatments for autoimmune diseases.

  Recruiting Quell Therapeutics Limited · London · NCT04838171

• Immune biomarkers to predict complications after liver transplantation

  This study tests immune biomarkers in adults after liver transplant to see if changes in markers relate to infections, rejection, or viral reactivation within the first year.

  Recruiting at 3 sites Hospital Italiano de Buenos Aires · Pilar, Buenos Aires and 2 other locations · NCT07875595

• Non-invasive test to predict early heart rejection in pediatric transplant patients

  This study tests non-invasive heart tests like cardiac MRI and blood markers to see if they can detect rejection in kids after heart transplant, potentially reducing the need for invasive biopsies.

  Recruiting at 22 sites Vanderbilt University Medical Center · Little Rock, Arkansas and 21 other locations · NCT07770659

• Multimodal prospective approach to understand acute and chronic lung transplant rejection

  This project will see if blood tests, airway sampling, imaging, and genetic analyses can identify which adults who have had or are being evaluated for a lung transplant will develop antibody‑mediated rejection and later chronic graft dysfunction.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07516379

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.